Leukemia: all 5,475 studies

Page 30 of 55. Open to participants first (629), then studies with results posted, then the rest; newest registration first within each.

• Alternative Splicing and Leukemia Initiating CellsStatus unknownNCT03156933
• A Clinical Study Evaluating the Safety and Efficacy of BinD19 Treatment in R/R ALL and Lymphoma SubjectsStatus unknownNCT03156101Phase 1/2
• Study of TBI-1501 for Relapsed or Refractory Acute Lymphoblastic LeukemiaActive, not recruitingNCT03155191Phase 1/2
• Study to Evaluate the Safety and Preliminary Efficacy of Ibrutinib and Pembrolizumab in Patients With Chronic Lymphocytic Leukemia (CLL) or Mantle Cell Lymphoma (MCL)Active, not recruitingNCT03153202Phase 1/2
• C-X-C Chemokine Receptor 4 in Chronic Lymphocytic LeukemiaStatus unknownNCT03150849
• Early Tapering of Immunosuppressive Agents to Immunomodulation to Improve Survival of AML PatientsStatus unknownNCT03150134Phase 4
• Effect of Different Exercises on Quality of Life of Leukemia Patients.CompletedNCT03147365Not applicable
• Pilot Study on the Infusion of ARI-0001 Cells in Patients With CD19+ Leukemia or Lymphoma Refractory to TherapyCompletedNCT03144583Phase 1
• Study of AMV564 in Patients With AMLCompletedNCT03144245Phase 1
• Comparing CGM and OGTT in Relation to Iron Overload Detected by Pancreas T2* MRI in High-Risk Hematology GroupWithdrawnNCT03141398
• Cessation of Tyrosine Kinase Inhibitors in Patients With Chronic-phase Chronic Myelogenous LeukaemiaStatus unknownNCT03131986
• BAY1436032 in Patients With Mutant IDH1(mIDH1) Advanced Acute Myeloid Leukemia (AML)CompletedNCT03127735Phase 1
• Study of Adoptive Cellular Therapy Using Autologous T Cells Transduced With Lentivirus to Express a CD33 Specific Chimeric Antigen Receptor in Patients With Relapsed or Refractory CD33-Positive Acute Myeloid LeukemiaTerminatedNCT03126864Phase 1
• A Phase Ib Study of CT053PTSA in Relapsed / Refractory Acute Myeloid Leukemia (AML)TerminatedNCT03125876Phase 1
• Combination Merestinib and LY2874455 for Patients With Relapsed or Refractory Acute Myeloid LeukemiaCompletedNCT03125239Phase 1
• Evaluate the Hematological Remission Rates and Survival Among Chinese Adult Patients With B-precursor ALLCompletedNCT03123887
• Interferon-α Prevents Leukemia Relapse of AML Patients After TransplantationWithdrawnNCT03121079Not applicable
• Metformin Reduce the Relapse Rate on Patients With B-cell Precursor (Ph+ Negative) Acute Lymphoblastic LeukemiaCompletedNCT03118128Not applicable
• ENDURE - Efficacy and Safety of AOP2014 With CML Patients in RemissionCompletedNCT03117816Phase 3
• Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and LymphomaActive, not recruitingNCT03117751Phase 2/3
• Donor-derived Anti-CD123-CART Cells for Recurred AML After Allo-HSCTStatus unknownNCT03114670Phase 1
• An Expanded Treatment Protocol (ETP) of Midostaurin (PKC412) in Patients 18 Years of Age or Older With Newly-diagnosed FLT3-mutated Acute Myeloid Leukemia (AML)No longer availableNCT03114228
• Anti-CD19 CAR T Infusion Combined With Allogeneic Stem Cell Transplantation for B-cell Leukemia/LymphomaStatus unknownNCT03110640Phase 1
• Blinatumomab in Adult Patients With Minimal Residual Disease (MRD) of B-precursor Acute Lymphoblastic LeukemiaCompletedNCT03109093Phase 2
• Gluten Free Diet in Diminishing Side Effects Patients With Acute Myeloid Leukemia Undergoing Induction ChemotherapyTerminatedNCT03108911Phase 2
• huJCAR014 CAR-T Cells in Treating Adult Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma or Acute Lymphoblastic LeukemiaTerminatedNCT03103971Phase 1
• Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD20CompletedNCT03097770Phase 1/2
• Long-term QoL in Acute Promyelocytic Leukemia Treated With ATO or Standard ChemotherapyStatus unknownNCT03096496
• Haploidentical Stem Cell Transplantation Using Post-Transplant CyclophosphamideTerminatedNCT03088709Phase 2
• Cellular Immunotherapy for Patients With High Risk Myelodysplastic Syndromes and Acute Myeloid LeukemiaStatus unknownNCT03083054Phase 1/2
• Open Label NK Cell Infusion (FATE-NK100) With Subq IL-2 in Adults With AMLCompletedNCT03081780Phase 1
• High Dose Donor Hematopoietic Stem Cell Infusion for Relapsed/Refractory AMLStatus unknownNCT03080922Phase 1/2
• The Use of Decitabine as Induction Therapy for Acute Myeloid Leukemia With Complex and/or Monosomal KaryotypeStatus unknownNCT03080766Phase 2
• Dasatinib Versus Nilotinib for Treatment Naïve Chronic Myeloid LeukemiaTerminatedNCT03079505Phase 3
• Anti-CD19 Chimeric Antigen Receptor (CAR)-Transduced T Cell Therapy for Patients With B Cell MalignanciesCompletedNCT03076437Phase 1/2
• Phase IV EORTC Quality of Life Module for Patients With Chronic Myeloid LeukemiaStatus unknownNCT03075969
• Expanded Access Study of Gilteritinib (ASP2215) in Patients With FMS-like Tyrosine Kinase 3 (FLT3) Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) or FLT3-Mutated AML in Complete Remission (CR) With Minimal Residual Disease (MRD)Approved for marketingNCT03070093
• Genetic Study of Familial Acute Lymphoblastic LeukemiaCompletedNCT03067584
• Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With AML or High Risk MDSCompletedNCT03066648Phase 1
• Randomized Study: Standard of Care With or Without Atorvastatin for Prevention of GVHD for Matched Unrelated Donor BMTWithdrawnNCT03066466Phase 3
• STAT Inhibitor OPB-111077, Decitabine and Venetoclax in Treating Patients With Acute Myeloid Leukemia That Is Refractory, Relapsed or Newly Diagnosed and Ineligible for Intensive ChemotherapyCompletedNCT03063944Phase 1
• A Phase 2a, Open-Label, Two Stage Study of Nerofe or Nerofe With Doxorubicin in Subjects With AML or MDSWithdrawnNCT03059615Phase 2
• DC/AML Fusion Cell Vaccine vs Observation in Patients Who Achieve a Chemotherapy-induced RemissionActive, not recruitingNCT03059485Phase 2
• Observational Study: Safety and Effectiveness of Obinutuzumab in Chronic Lymphocytic Leukemia in ArgentinaCompletedNCT03059251
• A Prospective, Interventional Study Assessing Response to Cytarabine, Daunorubicin and Etoposide (ADE) for First Relapse of Paediatric Acute Myeloid LeukemiaStatus unknownNCT03053206Phase 2
• Treatment Patterns and Key Healthcare Resource Use in Acute Myeloid Leukemia (AML) With or Without FMS-like Tyrosine Kinase-3 (FLT3) Mutation Study Based on Retrospective Chart ReviewCompletedNCT03047083
• Clinical Trial of Ara-C, Aclarubicin Combined With PEG-G-CSF for Initial Treatment of AML PatientsStatus unknownNCT03045627Phase 2
• Determining Change in Cardiovascular and Metabolic Risks in Patients With Chronic Phase Chronic Myeloid Leukemia Receiving BCR-ABL Tyrosine Kinase Inhibitor First-Line Therapy in the United StatesCompletedNCT03045120
• A Study of HDC/IL-2 Treatment in Chronic Myelomonocytic Leukemia (CMML)Status unknownNCT03040401Phase 1/2
• Safety and Pharmacokinetics of Oral F901318 (Fluconazole and Posaconazole) IN Aml LeukaemiaWithdrawnNCT03036046Phase 1/2
• Sequential Conditioning in Haploidentical Transplantation for Refractory Acute Myeloid LeukemiaCompletedNCT03035422Not applicable
• Study of the Intermediate Metabolism in Children With Acute Lymphoblastic Leukemia (ALL)Status unknownNCT03035344
• Efficacy and Safety of Chidamide in CBF LeukemiaActive, not recruitingNCT03031262Phase 1/2
• A Study of ARGX-110 in Combination With Azacytidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) or High Risk Myelodysplatic Syndrome (MDS)CompletedNCT03030612Phase 1/2
• CART-19 Cells For MRD Positive CD19+ ALLStatus unknownNCT03027739Phase 2/3
• Study of Allogeneic Double Negative T Cells (DNT-UHN-1) in Patients With High Risk Acute Myeloid LeukemiaCompletedNCT03027102Phase 1
• Decitabine Versus Conventional Chemotherapy for Maintenance Therapy of Acute Myeloid Leukemia With t(8;21)Status unknownNCT03026842Phase 4
• Feasibility Study of Intermediate Doses of ARA-C With Autologous SCT as Consolidation of Low/Intermediate-risk AMLStatus unknownNCT03023384
• A Phase I Study Evaluating Safety and Efficacy of C-CAR011 Treatment in Adult Subjects With r/r CD19+B-ALLStatus unknownNCT03018093Phase 1
• Administration of Autologous CAR-T CD19 Antigen With Inducible Safety Switch in Patients With Relapsed/Refractory ALLActive, not recruitingNCT03016377Phase 1
• Comparing Two Diets in Patients Undergoing HSCT or Remission Induction Chemo for Acute Leukemia and MDS (UF-BMT-LDND-101)TerminatedNCT03016130Phase 3
• Home-exercise Program for Children and Adolescent Survivors of Acute Lymphoblastic LeukemiaCompletedNCT03005392Phase 1/2
• Evaluation of ProALL miRs in Blood Specimen for Prediction of ALL Relapse RiskStatus unknownNCT03000335
• Haploidentical BMT With Post-Transplant Cyclophosphamide and BendamustineCompletedNCT02996773Phase 1
• CX-01 Combined With Azacitidine in the Treatment of Relapsed or Refractory Myelodysplastic Syndrome and Acute Myeloid LeukemiaCompletedNCT02995655Phase 1
• Clonal Evolution of B Cells in High-risk CLL After Idelalisib-rituximabWithdrawnNCT02993536
• Efficacy and Safety of Ibrutinib in Patients With CLL and Other Indolent B-cell Lymphomas Who Are Chronic Hepatitis B Virus Carriers or Occult Hepatitis B Virus CarriersStatus unknownNCT02991638Phase 3
• Role of Microparticles in the Coagulopathy of Acute Promyelocytic LeukemiaStatus unknownNCT02991066
• First Report, Five Years Experience of the Acute Leukemia Work GroupStatus unknownNCT02990104
• Decitabine in Combination With Low-dose Cytarabine in Elderly Patients With Acute Myeloid LeukemiaStatus unknownNCT02985372Phase 3
• Comparative Evaluation of Results of Allogeneic Hematopoietic Stem Cells Versus Ponatinib in CML Patients Carrying a Mutation T315ICompletedNCT02981784
• Study of Safety,Efficacy and Pharmacokinetics of CT-1530 in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's MacroglobulinemiaStatus unknownNCT02981745Phase 1/2
• Phase I Study of S64315 Administred Intravenously in Patients With Acute Myeloid Leukaemia or Myelodysplastic SyndromeCompletedNCT02979366Phase 1
• Study of Cemivil® (Imatinib) in Chronic Myeloid Leukemia Patients in JordanCompletedNCT02977312
• A Collaborative Palliative and Oncology Care Model for Patients With Acute Myeloid LeukemiaCompletedNCT02975869Not applicable
• CD19 CAR T Cells in Patients With Resistant or Refractory CD19+ Acute Lymphoblastic LeukemiaCompletedNCT02975687Phase 1
• A Study to Determine Safety, Feasibility and Efficacy of JCAR015 in Adult Subjects With B-Cell Acute Lymphoblastic LeukemiaWithdrawnNCT02973191Phase 1/2
• A Phase I Trial of 4SCAR19 Cells in the Treatment of Relapsed and Refractory B Cell LeukemiaStatus unknownNCT02968472Phase 1
• A Study of Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaActive, not recruitingNCT02966756Phase 2
• Engineered Donor Stem Cell Transplant in Treating Patients With Hematologic MalignanciesCompletedNCT02960646Phase 1
• Biobehavioral Intervention to Enhance Hematopoietic Stem Cell Transplant RecoveryCompletedNCT02955043Not applicable
• CAR-pNK Cell Immunotherapy for Relapsed/Refractory CD33+ AMLStatus unknownNCT02944162Phase 1/2
• A Clinical Research of CD123-Targeted CAR-T in Myeloid MalignanciesStatus unknownNCT02937103Phase 1/2
• Risk Stratification-directed Therapy for AML With t(8;21) /AML1-ETO+CompletedNCT02936089Not applicable
• Immunotherapy for High Risk/Relapsed CD19+ Acute Lymphoblastic Leukaemia, B-cell Non-Hodgkin's Lymphoma (B-NHL) and Chronic Lymphocytic Leukaemia (CLL)/ Small Lymphocytic Lymphoma (SLL) Using CAR T-cells to Target CD19Active, not recruitingNCT02935257Phase 1
• A Clinical Research of CD22-Targeted CAR-T in B Cell MalignanciesStatus unknownNCT02935153Phase 1/2
• CD19-redirected Autologous Cells (CAR-CD19 T Cells)Status unknownNCT02933775Phase 1
• G-CSF Alone or Combination With GM-CSF on Prevention and Treatment of Infection in Children With Malignant TumorStatus unknownNCT02933333Phase 4
• Safety and Dose Finding Study of Neratinib in Children and Young Adults With Cancer That Has Returned or Not Responded to TreatmentActive, not recruitingNCT02932280Phase 1/2
• PreventiOn of DYSbioSis Complications With Autologous FMT in AML PatientsCompletedNCT02928523Phase 1/2
• Mechanisms of Idelalisib-Associated Diarrhea in Patients With Relapsed Chronic Lymphocytic Leukemia, Indolent Non-hodgkin Lymphoma, or Small Lymphocytic LymphomaTerminatedNCT02928510
• Beat AML Core StudyCompletedNCT02927106
• Fludarabine and Cytarabine Versus High-dose Cytarabine for CBF-AMLCompletedNCT02926586Phase 4
• The Safety and Efficacy of CART-19 Cells in B-cell Acute Lymphoblastic Leukemia (B-ALL).Status unknownNCT02924753Phase 1
• Study to Evaluate Safety and Tolerability of XmAb13676 (Plamotamab) in Patients With CD20-expressing Hematologic MalignanciesCompletedNCT02924402Phase 1
• Clinical Trial of BP1001 (Liposomal Grb2 Antisense Oligonucleotide) in Combination With Dasatinib in Patients With Ph + CML Who Have Failed TKI, Ph+ AML, Ph+ MDSWithdrawnNCT02923986Phase 1/2
• A Study to Analyze the Occurrence of Transformation From Myelodysplastic Syndrome to Acute Myeloid Leukemia in Patients With Myelodysplastic Syndrome Who Received Revlimid® 5 mg Capsules and Who Are Continuing or no Longer Continuing Revlimid TreatmentCompletedNCT02921815
• Dose-escalation Study of Oral Administration of S 055746 in Patients With Acute Myeloid Leukaemia or Myelodysplastic SyndromeCompletedNCT02920541Phase 1
• Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators' Expression in Allogeneic SCT Using FluBuATGCompletedNCT02916979Phase 1
• A Study of Obinutuzumab Evaluating Efficacy, Safety and Cost of Disease Management in Participants With Chronic Lymphocytic Leukemia and ComorbiditiesCompletedNCT02915224

← Leukemia overview